Replies to post #255 on RegeneRx Biopharmaceuticals Inc (RGRX)

[subslover]

RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
ReGenTree Also Developing New NK Ophthalmic Formulation
PR Newswire
https://www.otcmarkets.com/stock/RGRX/news/RegeneRx-Joint-Venture-Announces-Efficacy-Results-of-Neurotrophic-Keratopathy-Phase-3-Clinical-Trial-with-RGN-259?id=262010